Becky K.C. Chan
YOU?
Author Swipe
View article: A combined enteric neuron-gastric tumor organoid reveals metabolic vulnerabilities in gastric cancer
A combined enteric neuron-gastric tumor organoid reveals metabolic vulnerabilities in gastric cancer Open
The discrepancy between organoid and immortalized cell line cultures for cancer target discovery remains unclear. Here, our multi-tiered clustered regularly interspaced short palindromic repeats (CRISPR) screens reveal in vivo-relevant met…
View article: Supplementary Table S6 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S6 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S6
View article: Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinat…
View article: Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S1
View article: Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S4
View article: Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Figures and Supplementary Materials and Methods
View article: Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinat…
View article: Supplementary Table S6 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S6 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S6
View article: Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S4
View article: Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S5
View article: Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S5
View article: Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S2
View article: Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S3
View article: Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Figures and Supplementary Materials and Methods
View article: Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S3
View article: Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S2
View article: Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment Open
Supplementary Table S1
View article: Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities
Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities Open
The genome-editing Cas9 protein uses multiple amino-acid residues to bind the target DNA. Considering only the residues in proximity to the target DNA as potential sites to optimise Cas9’s activity, the number of combinatorial variants to …
View article: High-fidelity KKH variant of <i>Staphylococcus aureus</i> Cas9 nucleases with improved base mismatch discrimination
High-fidelity KKH variant of <i>Staphylococcus aureus</i> Cas9 nucleases with improved base mismatch discrimination Open
The Cas9 nuclease from Staphylococcus aureus (SaCas9) holds great potential for use in gene therapy, and variants with increased fidelity have been engineered. However, we find that existing variants have not reached the greatest accuracy …
View article: Extensible combinatorial CRISPR screening in mammalian cells
Extensible combinatorial CRISPR screening in mammalian cells Open
View article: A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets
A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets Open
View article: Publisher Correction: Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9
Publisher Correction: Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9 Open
View article: Hepatic artery pseudoaneurysm rupture
Hepatic artery pseudoaneurysm rupture Open
View article: Gastric outlet obstruction - pancreatic cancer
Gastric outlet obstruction - pancreatic cancer Open
View article: CT-guided pudendal nerve infiltration
CT-guided pudendal nerve infiltration Open
View article: Congenital absence of the left main pulmonary artery
Congenital absence of the left main pulmonary artery Open
View article: Abscess of the pinna
Abscess of the pinna Open